These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

182 related items for PubMed ID: 24440046

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
    Nayak TK, Regino CA, Wong KJ, Milenic DE, Garmestani K, Baidoo KE, Szajek LP, Brechbiel MW.
    Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1368-76. PubMed ID: 20155263
    [Abstract] [Full Text] [Related]

  • 3. Potential of a Cetuximab-based radioimmunotherapy combined with external irradiation manifests in a 3-D cell assay.
    Ingargiola M, Runge R, Heldt JM, Freudenberg R, Steinbach J, Cordes N, Baumann M, Kotzerke J, Brockhoff G, Kunz-Schughart LA.
    Int J Cancer; 2014 Aug 15; 135(4):968-80. PubMed ID: 24615356
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
    Eke I, Ingargiola M, Förster C, Kunz-Schughart LA, Baumann M, Runge R, Freudenberg R, Kotzerke J, Heldt JM, Pietzsch HJ, Steinbach J, Cordes N.
    Int J Radiat Biol; 2014 Aug 15; 90(8):678-86. PubMed ID: 24597752
    [Abstract] [Full Text] [Related]

  • 7. Cellular and molecular properties of (90)Y-labeled cetuximab in combination with radiotherapy on human tumor cells in vitro.
    Saki M, Toulany M, Sihver W, Zenker M, Heldt JM, Mosch B, Pietzsch HJ, Baumann M, Steinbach J, Rodemann HP.
    Strahlenther Onkol; 2012 Sep 15; 188(9):823-32. PubMed ID: 22875052
    [Abstract] [Full Text] [Related]

  • 8. PET imaging of tumor angiogenesis in mice with VEGF-A-targeted (86)Y-CHX-A″-DTPA-bevacizumab.
    Nayak TK, Garmestani K, Baidoo KE, Milenic DE, Brechbiel MW.
    Int J Cancer; 2011 Feb 15; 128(4):920-6. PubMed ID: 20473899
    [Abstract] [Full Text] [Related]

  • 9. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
    Perk LR, Visser GW, Vosjan MJ, Stigter-van Walsum M, Tijink BM, Leemans CR, van Dongen GA.
    J Nucl Med; 2005 Nov 15; 46(11):1898-906. PubMed ID: 16269605
    [Abstract] [Full Text] [Related]

  • 10. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
    Liu Z, Ma T, Liu H, Jin Z, Sun X, Zhao H, Shi J, Jia B, Li F, Wang F.
    Mol Pharm; 2014 Mar 03; 11(3):800-7. PubMed ID: 24472064
    [Abstract] [Full Text] [Related]

  • 11. A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
    Price EW, Edwards KJ, Carnazza KE, Carlin SD, Zeglis BM, Adam MJ, Orvig C, Lewis JS.
    Nucl Med Biol; 2016 Sep 03; 43(9):566-576. PubMed ID: 27419360
    [Abstract] [Full Text] [Related]

  • 12. Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
    Kelly MP, Lee ST, Lee FT, Smyth FE, Davis ID, Brechbiel MW, Scott AM.
    Prostate; 2009 Jan 01; 69(1):92-104. PubMed ID: 18942092
    [Abstract] [Full Text] [Related]

  • 13. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    Song IH, Lee TS, Park YS, Lee JS, Lee BC, Moon BS, An GI, Lee HW, Kim KI, Lee YJ, Kang JH, Lim SM.
    J Nucl Med; 2016 Jul 01; 57(7):1105-11. PubMed ID: 26917708
    [Abstract] [Full Text] [Related]

  • 14. HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.
    Nayak TK, Garmestani K, Milenic DE, Baidoo KE, Brechbiel MW.
    PLoS One; 2011 Mar 25; 6(3):e18198. PubMed ID: 21464917
    [Abstract] [Full Text] [Related]

  • 15. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma.
    Niu G, Sun X, Cao Q, Courter D, Koong A, Le QT, Gambhir SS, Chen X.
    Clin Cancer Res; 2010 Apr 01; 16(7):2095-105. PubMed ID: 20215534
    [Abstract] [Full Text] [Related]

  • 16. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM, Neri D, Leemans CR, Budde M, Dinkelborg LM, Stigter-van Walsum M, Zardi L, van Dongen GA.
    J Nucl Med; 2006 Jul 01; 47(7):1127-35. PubMed ID: 16818947
    [Abstract] [Full Text] [Related]

  • 17. Fractionated radioimmunotherapy with ⁹⁰Y-labeled fully human anti-CEA antibody.
    Hanaoka H, Kuroki M, Yamaguchi A, Achmad A, Iida Y, Higuchi T, Oriuchi N, Tsushima Y, Endo K.
    Cancer Biother Radiopharm; 2014 Mar 01; 29(2):70-6. PubMed ID: 24299067
    [Abstract] [Full Text] [Related]

  • 18. Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model.
    Hoeben BA, Molkenboer-Kuenen JD, Oyen WJ, Peeters WJ, Kaanders JH, Bussink J, Boerman OC.
    Int J Cancer; 2011 Aug 15; 129(4):870-8. PubMed ID: 20957635
    [Abstract] [Full Text] [Related]

  • 19. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
    Chakravarty R, Chakraborty S, Sarma HD, Nair KV, Rajeswari A, Dash A.
    J Labelled Comp Radiopharm; 2016 Jul 15; 59(9):354-63. PubMed ID: 27264196
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR.
    Chan C, Fonge H, Lam K, Reilly RM.
    Nucl Med Biol; 2020 Jul 15; 80-81():37-44. PubMed ID: 31706737
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.